Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels
Copyright © 2012. Published by Elsevier B.V..
Cisplatin-induced acute kidney injury (AKI) is a major concern among clinicians in prescribing cisplatin-based chemotherapy. This study evaluated and compared the ability of urinary biomarkers, including urinary neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and the urinary albumin to creatinine ratio (ACR) to predict cisplatin-induced AKI. Thirty-three cancer patients receiving cisplatin-based chemotherapy were prospectively studied, including 10 (30%) who developed AKI (the study group). Changes of urinary biomarkers were compared at 4 hours, 8 hours, and 12 hours, and 1 day, 2 days, 3 days, and 4 days after cisplatin intravenous infusions (75mg/m(2)) versus the baseline. There was a significant increase in urinary NGAL levels from 12 hours to 4 days (p<0.05) compared to baseline after cisplatin infusion in the AKI group. The magnitude of these changes over time differed significantly by group (p<0.001). The area under the receiver operating curve describing the relationship between urinary NGAL levels and AKI within 12 hours was 0.865 (95% confidence interval=0.691-1.000). Urinary NGAL levels independently predicted AKI 12 hours after cisplatin (p=0.045) after adjustments for age, gender, body mass index, baseline serum creatinine, and urinary total protein. Urinary NGAL levels may be an early biomarker of AKI in patients receiving cisplatin-based treatment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2013 |
---|---|
Erschienen: |
2013 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
The Kaohsiung journal of medical sciences - 29(2013), 6 vom: 15. Juni, Seite 304-11 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lin, Hugo You-Hsien [VerfasserIn] |
---|
Links: |
---|
Themen: |
AYI8EX34EU |
---|
Anmerkungen: |
Date Completed 10.07.2014 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.kjms.2012.10.004 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM227594231 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM227594231 | ||
003 | DE-627 | ||
005 | 20231224074038.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2013 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.kjms.2012.10.004 |2 doi | |
028 | 5 | 2 | |a pubmed24n0758.xml |
035 | |a (DE-627)NLM227594231 | ||
035 | |a (NLM)23684135 | ||
035 | |a (PII)S1607-551X(12)00302-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lin, Hugo You-Hsien |e verfasserin |4 aut | |
245 | 1 | 0 | |a Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels |
264 | 1 | |c 2013 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.07.2014 | ||
500 | |a Date Revised 08.04.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2012. Published by Elsevier B.V. | ||
520 | |a Cisplatin-induced acute kidney injury (AKI) is a major concern among clinicians in prescribing cisplatin-based chemotherapy. This study evaluated and compared the ability of urinary biomarkers, including urinary neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and the urinary albumin to creatinine ratio (ACR) to predict cisplatin-induced AKI. Thirty-three cancer patients receiving cisplatin-based chemotherapy were prospectively studied, including 10 (30%) who developed AKI (the study group). Changes of urinary biomarkers were compared at 4 hours, 8 hours, and 12 hours, and 1 day, 2 days, 3 days, and 4 days after cisplatin intravenous infusions (75mg/m(2)) versus the baseline. There was a significant increase in urinary NGAL levels from 12 hours to 4 days (p<0.05) compared to baseline after cisplatin infusion in the AKI group. The magnitude of these changes over time differed significantly by group (p<0.001). The area under the receiver operating curve describing the relationship between urinary NGAL levels and AKI within 12 hours was 0.865 (95% confidence interval=0.691-1.000). Urinary NGAL levels independently predicted AKI 12 hours after cisplatin (p=0.045) after adjustments for age, gender, body mass index, baseline serum creatinine, and urinary total protein. Urinary NGAL levels may be an early biomarker of AKI in patients receiving cisplatin-based treatment | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Acute-Phase Proteins |2 NLM | |
650 | 7 | |a Cystatin C |2 NLM | |
650 | 7 | |a LCN2 protein, human |2 NLM | |
650 | 7 | |a Lipocalin-2 |2 NLM | |
650 | 7 | |a Lipocalins |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
650 | 7 | |a Creatinine |2 NLM | |
650 | 7 | |a AYI8EX34EU |2 NLM | |
650 | 7 | |a Cisplatin |2 NLM | |
650 | 7 | |a Q20Q21Q62J |2 NLM | |
700 | 1 | |a Lee, Su-Chu |e verfasserin |4 aut | |
700 | 1 | |a Lin, Sheng-Fung |e verfasserin |4 aut | |
700 | 1 | |a Hsiao, Hui-Hua |e verfasserin |4 aut | |
700 | 1 | |a Liu, Yi-Chang |e verfasserin |4 aut | |
700 | 1 | |a Yang, Wen-Chi |e verfasserin |4 aut | |
700 | 1 | |a Hwang, Daw-Yang |e verfasserin |4 aut | |
700 | 1 | |a Hung, Chi-Chih |e verfasserin |4 aut | |
700 | 1 | |a Chen, Hung-Chun |e verfasserin |4 aut | |
700 | 1 | |a Guh, Jinn-Yuh |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Kaohsiung journal of medical sciences |d 1996 |g 29(2013), 6 vom: 15. Juni, Seite 304-11 |w (DE-627)NLM086492993 |x 2410-8650 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2013 |g number:6 |g day:15 |g month:06 |g pages:304-11 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.kjms.2012.10.004 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 29 |j 2013 |e 6 |b 15 |c 06 |h 304-11 |